NCT00465595View on ClinicalTrials.gov

Psychopharmacology of Psilocybin in Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2016

Conditions
Depressive SymptomsAnxietyCancer
Interventions
DRUG

psilocybin

The dose of psilocybin received in the two sessions will range anywhere from low to high.

Trial Locations (1)

21224

Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Campus, Baltimore

Sponsors
All Listed Sponsors
collaborator

Heffter Research Institute

OTHER

lead

Johns Hopkins University

OTHER